Chemicon International and Stem Cell Sciences Announce Launch of ESGRO Complete™ Product Line
07 March 06
New Grade of Serum and Feeder-Free Media for Mouse Embryonic Stem Cell Expansion
Serologicals Corporation have announced that Chemicon International, Inc., its wholly-owned subsidiary, and Stem Cell Sciences plc (SCS) are launching the ESGRO Complete™ product line for murine embryonic stem (ES) cell culture, following the establishment of an exclusive agreement on November 3, 2005.
Chemicon will exclusively market the licensed ESGRO Complete™ Clonal Grade Medium for serum-free, feeder-free expansion of mouse ES cells. The product, developed by SCS’s SC Proven division, is the first complete, defined medium that enables the large-scale, consistent production of mouse ES cells for the use in world-wide research and drug discovery markets. To complement the offering, Chemicon will be releasing other media and reagents needed for routine mouse ES cell culture that have been specifically engineered and validated for use in this serum-free system. The ESGRO Complete™ product line will broaden Chemicon’s offering within the stem cell culture market and will compliment the current portfolio of innovative reagents and technologies that are already being supplied to its customer base.
Jeffrey D. Linton, President of Chemicon and Upstate, Serologicals’ Research Segment companies said “The ESGRO Complete™ product line is a great leap forward over the existing methodologies used by stem cell researchers today. This is a culmination of our earlier agreement with Stem Cell Sciences to commercialize this technology through our Research segment, and is yet another example of how Chemicon is establishing itself as a leading company in the stem cell research arena.” “We are very excited about the launch of our first cell culture media product. This will generate revenue streams in the near term and marks a major milestone in our development,” said Peter Mountford, CEO of Stem Cell Sciences plc. “The launch validates our technology and will contribute to the wider adoption of stem cells within the global drug discovery market. We look forward to our continued collaboration with Chemicon and the opportunity to expand the stem cell culture product offering in due course.”
Chemicon International, Inc. offers a broad range of research products, including specialty reagents, kits, antibodies, and custom products and services, to customers working in the areas of neuroscience, stem cell biology, cancer, and infectious disease research. It is also a leading supplier of monoclonal antibodies, conjugates, antibody blends and molecular-based detection kits for use in diagnostic laboratories. Chemicon focuses on basic and biomedical research, drug discovery, and diagnostics, allowing it to serve thousands of customers worldwide in the academic, clinical, biotechnology, and pharmaceutical sectors. Acquired in 2003, Chemicon is a Serologicals company, based in Temecula, CA.
More information on Seriologicals
|
